» Articles » PMID: 32687947

The USP22 Promotes the Growth of Cancer Cells Through the DYRK1A in Pancreatic Ductal Adenocarcinoma

Overview
Journal Gene
Specialty Molecular Biology
Date 2020 Jul 21
PMID 32687947
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

As a member of the ubiquitin-specific protease (USP) family, USP22 could remove ubiquitin moieties from its target proteins to control the function of the target proteins. Accumulating studies show that USP22 essentially participates in diverse types of cancer as an oncogene-like protein. However, the roles of USP22 in human pancreatic ductal adenocarcinoma (PDAC) and the underlying mechanism are unknown. Here we report that USP22 promotes the growth of PDAC cells by promoting the expression of dual-specificity tyrosine regulated kinase 1A (DYRK1A). Our results showed that the expression levels of USP22 were up-regulated in human PDAC tissues and cell lines (BxPC-3, AsPC-1, MIA-PaCa-2, PANC-1, and CAPAN-1). Lentivirus-mediated knockdown of USP22 repressed the rate of proliferation and capacity of colony formation of BxPC3 and CAPAN1 cancer cells and USP22 overexpression promoted the proliferation and capacity of the colony formation of BxPC3 and CAPAN1 cancer cells. The further mechanism study showed that USP22 elevated the expression of the mRNA and protein levels of DYRK1A in PDAC cancer cells. Inhibition of DYRK1A with EHT-5732 or lentivirus-mediated knockdown of DYRK1A blocked the function of USP22 overexpression in the regulation of the proliferation and colony formation of PDAC cells. Taken together, our findings demonstrated that USP22 overexpression in PDAC promoted the growth of the cancer cells partially through upregulating the expression of DYRK1A.

Citing Articles

Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.

Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P Int J Biol Sci. 2025; 21(1):63-74.

PMID: 39744438 PMC: 11667816. DOI: 10.7150/ijbs.101861.


An Overview of the Deubiquitinase USP53: A Promising Diagnostic Marker and Therapeutic Target.

Xia G, Guo Y, Zhang J, Han M, Meng X, Lv J Curr Protein Pept Sci. 2024; 25(9):708-718.

PMID: 39300775 PMC: 11348463. DOI: 10.2174/0113892037292440240518194922.


Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.

Du L, Wilson B, Li N, Shah R, Dalilian M, Wang D J Nat Prod. 2023; 86(10):2283-2293.

PMID: 37843072 PMC: 10616853. DOI: 10.1021/acs.jnatprod.3c00394.


Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.

Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B MedComm (2020). 2023; 4(3):e261.

PMID: 37143582 PMC: 10152985. DOI: 10.1002/mco2.261.


Histone Modifications Represent a Key Epigenetic Feature of Epithelial-to-Mesenchyme Transition in Pancreatic Cancer.

Xu Y, Zhu Q Int J Mol Sci. 2023; 24(5).

PMID: 36902253 PMC: 10003015. DOI: 10.3390/ijms24054820.